União Europeia - maltês - EMA (European Medicines Agency)

gilead sciences ireland uc - elvitegravir, kobikistat, emtricitabine, tenofovir alafenamide - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - genvoya huwa indikat għall-kura ta ' l-adulti u l-adolexxenti (korp età 12-il sena u aktar antiki mal-piż mill-anqas 35 kg) infettati bil-virus ta ' immunodefiċjenza umani 1 (hiv 1) mingħajr ebda mutazzjonijiet magħrufa assoċjati mal-reżistenza għall-klassi ta ' inibitur ta ' integrase, emtricitabine jew tenofovir.

União Europeia - maltês - EMA (European Medicines Agency)

avimedical b.v. - itraconazole - antimikotiċi għall-użu sistemiku-derivati triazole, itraconazole - avjan - għat-trattament ta ' asperġillożi u kandidjasi fil-ħbieb l-għasafar,.

União Europeia - maltês - EMA (European Medicines Agency)

roche registration gmbh - oseltamivir - influwenza, bniedem - antivirali għal użu sistemiku - it-trattament tal-influenzatamiflu hija indikata fl-adulti u t-tfal inkluż il-perjodu sħiħ ta'trabi tat-twelid li tippreżenta b'sintomi tipiċi ta'l-influwenza, meta l-virus ta'l-influwenza qiegħed jinfirex fil-komunità. l-effikaċja ntweriet meta t-trattament inbeda fi żmien jumejn mill-bidu tas-sintomi. il-prevenzjoni ta influenzapost-espożizzjoni-prevenzjoni, f'individwi minn sena'l fuq wara li jkollhom kuntatt ma'każ ta'influwenza ddijanjostikat klinikament meta l-virus ta'l-influwenza qiegħed jinfirex fil-komunità. l-użu xieraq ta ' tamiflu għall-prevenzjoni ta'l-influwenza għandu jiġi determinat fuq bażi ta'każ b'każ skond iċ-ċirkustanzi u l-popolazzjoni li teħtieġ il-protezzjoni. f'sitwazzjonijiet eċċezzjonali (e. fil-każ ta'nuqqas ta'qbil bejn il-ċirkulazzjoni u l-virus tal-vaċċin razez, u f'sitwazzjoni pandemika) ta'prevenzjoni fl-istaġun tista'tiġi kkunsidrata f'individwi minn sena jew akbar fl-età. tamiflu hija indikata għall-prevenzjoni wara espożizzjoni ta 'l-influwenza fit-trabi ta' anqas minn sena 1 ta ' età waqt illi tfaqqa'xi influwenza pandemika. tamiflu mhux sostitut għal tilqima kontra l-influwenza. l-użu ta'l-antivirali għall-kura u l-prevenzjoni ta'l-influwenza għandu jiġi ddeterminat fuq il-bażi ta ' rakkomandazzjonijiet uffiċjali. id-deċiżjonijiet dwar l-użu ta'oseltamivir għall-kura u l-profilassi għandhom jieħdu f'kunsiderazzjoni dak li huwa magħruf dwar il-karatteristiċi tal-ċirkolazzjoni-vajrusis tal-influwenza, l-informazzjoni disponibbli dwar l-influwenza tad-droga fis-suxxettibilità mudelli għal kull istaġun u l-impatt tal-marda f'żoni ġeografikament differenti u l-popolazzjonijiet ta ' pazjenti.

União Europeia - maltês - EMA (European Medicines Agency)

covis pharma europe b.v. - aclidinium bromide, formoterol fumarate dihydrate - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - duaklir genuair huwa indikat bħala trattament ta 'manteniment tal-bronkodilatur biex itaffi sintomi f'pazjenti adulti b'mard pulmonari ostruttiv kroniku (copd).

União Europeia - maltês - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - eprinomectin, fipronil, praziquantel, (s) -methoprene - antiparasitic products, insecticides and repellents, avermectins, eprinomectin, combinations, - qtates - għall-qtates, jew f'riskju minn infestazzjonijiet imħallta permezz ta 'ċestodi, nematodi u ektoparassiti. il-prodott mediċinali veterinarju huwa esklussivament indikat meta l-tliet gruppi huma maħsuba fl-istess ħin. ectoparasitestreatment u l-prevenzjoni ta ' infestazzjonijiet minn briegħed (ctenocephalides felis). l-eliminazzjoni tal-briegħed fi żmien 24 siegħa. trattament wieħed jippreveni t-infestazzjonijiet għal mill-inqas xahar. il-prevenzjoni ta'l-ambjent tal-briegħed-kontaminazzjoni billi jinibixxi l-iżvilupp tal-briegħed immaturi-istadji (bajd, il-larva u l-pupi) għal aktar minn xahar. il-prodott jista 'jintuża bħala parti minn strateġija ta' trattament għall-kontroll tad-dermatite tal-allerġija tal-briegħed (fad). it-trattament u l-prevenzjoni ta ' infestazzjonijiet bil-qurdien (ixodes ricinus). l-eliminazzjoni tal-qurdien fi żmien 48 siegħa. trattament wieħed jippreveni t-infestazzjonijiet sa 3 ġimgħat. it-trattament tal-notoedric mange (notoedres cati). cestodestreatment ta ' infestazzjonijiet bil-dud (dipylidium caninum, taenia taeniaeformis, echinococcus multilocularis, joyeuxiella pasqualei (adulti), u joyeuxiella fuhrmanni (adulti)). nematodestreatment ta ' infestazzjonijiet bil-ħniex gastro-intestinali (l3, l4-larva u l-adulti tal-toxocara cati, adulti tat-toxascaris leonina, larva l4 u l-adulti tal-ancylostoma tubaeforme u ancylostoma ceylanicum, u l-adulti tal-ancylostoma brazilienze). it-trattament ta ' infestazzjonijiet bil-feline lungworms (larva l3, l4-larva u l-adulti tal-aelurostrongylus abstrusus, larva l4 u l-adulti tal-troglostrongylus brevior). it-trattament ta ' infestazzjonijiet bil-vesical dud (capillaria plica). il-prevenzjoni tal-mard tal-heartworm (dirofilaria immitis larva) għal xahar.

União Europeia - maltês - EMA (European Medicines Agency)

corza medical gmbh - fibrinoġen uman, trombina umana - hemostasi, kirurġiċi - sustanzi kontra l-emorraġija - tachosil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.

União Europeia - maltês - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - vylaer spiromax huwa indikat fl-adulti ta '18-il sena' l fuq biss. asthmavylaer spiromax huwa indikat fit-trattament regolari ta ' l-ażżma, fejn l-użu tal-kombinazzjoni (kortikosterojdi meħuda man-nifs u li jaħdem fit-tul β2 adrenoceptor agonist) huwa xieraq:f'pazjenti li mhumiex adegwatament ikkontrollati bil-kortikosterojdi meħuda man-nifs u l - "kif meħtieġ" man-nifs qasir waqt li jaġixxi β2 adrenoceptor agonisti. fjorin pazjenti li diġà ikkontrollati adegwatament fuq iż-żewġ kortikosterojdi meħuda man-nifs u li jaħdem fit-tul β2 adrenoceptor agonisti. copdsymptomatic-trattament ta ' pazjenti b'indeboliment serju copd (fev1 < 50% mbassra-normal) u l-istorja tal-aggravar tal-attakki ripetuti, li għandhom sinifikanti sintomi minkejja regolari it-terapija b'taġixxi fit-tul bronkodilataturi.

União Europeia - maltês - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - epatite Ċ, kronika - antivirali għal użu sistemiku - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.

União Europeia - maltês - EMA (European Medicines Agency)

sandoz gmbh - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; arthritis, juvenile rheumatoid; crohn disease; skin diseases, papulosquamous - immunosoppressanti - rheumatoid arthritishyrimoz in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hyrimoz jista 'jingħata bħala monoterapija f'kaz ta' intolleranza għal methotrexate jew meta trattamenti fit-tul b'methotrexate mhux adattat. adalimumab ġie muri li jnaqqas ir-rata ta 'progressjoni tal-ħsara fil-ġogi kif imkejjel permezz ta' x-ray, u li jtejjeb il-funzjoni fiżika, meta jingħata flimkien ma ' methotrexate. juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritishyrimoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). hyrimoz jista 'jingħata bħala monoterapija f'kaz ta' intolleranza għal methotrexate jew meta trattamenti fit-tul b'methotrexate mhux adattat. adalimumab ma ġiex studjat f'pazjenti li għandhom inqas minn 2 snin. - enthesitis-related arthritishyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritis- ankylosing spondylitis (as)hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. - axial spondyloarthritis without radiographic evidence of ashyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. psoriatic arthritishyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumab ġie muri li jnaqqas ir-rata ta 'progressjoni tal-ħsara fil-ġogi periferali kif imkejjel permezz ta' x-ray f'pazjenti b'sottotipi poliartikulari simmetriċi tal-marda, u li jtejjeb il-funzjoni fiżika. psoriasishyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishyrimoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy. crohn’s diseasehyrimoz is indicated for treatment of moderately to severely active crohn’s disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehyrimoz is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies.  paediatric ulcerative colitishyrimoz is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. ulcerative colitishyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishyrimoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

União Europeia - maltês - EMA (European Medicines Agency)

ratiopharm gmbh - desloratadine - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - anti-istaminiċi għall-użu sistemiku, - desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician.